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The ability to translocate the cellular membranes and gain
access to the cell interior, including the different cellular
compartments, still remains a major obstacle in current drug
development. Peptide mediated delivery of bioactive molecules
appears to be a technology that in many aspects is superior to
commonly used delivery agents. Reported high delivery yield,
low toxicity and the possibility to add diverse modifications to
the peptide backbone make peptides an excellent candidate for
future drug delivery platforms. So-called cell-penetrating
peptides (CPPs), also often referred to as protein transduction
domains (PTDs), Trojan peptides or membrane translocating
sequences (MTS), have in recent years shown great potential in
the field of drug delivery. Current publications show that CPPs
can deliver a wide range of bioactive molecules such as proteins,
peptides, oligonucleotides (ON), and nano-particles to a variety
cell types and to different cellular compartments, both in vivo
and in vitro. The peptides named CPPs vary greatly in size,
amino acid sequence, and charge, but share the common feature
that they have the ability to rapidly translocate the plasma
membrane and enable delivery to the cytoplasm or nucleus [1].
The idea to use peptides used as delivery vectors, i.e. CPPs,
originates fromso-calledmembrane shuttlingproteins such as the
Drosophila homeobox protein Antennapedia, the HIV-1 tran-
scriptional factor TAT, and the capsid protein VP22 fromHSV-1.
The field started in 1988, when Green et al. showed that the viral
protein TAT rapidly translocate over cellular membrane, into the
cytoplasm [2]. Later, the same properties were shown for a
Drosophila homeobox protein. In 1994, Alain Prochiantz’ group
demonstrated that a short, 16aminoacid (aa)peptidederived from
the third loop of theAntennapedia proteinwas responsible for the
cellular translocation of the whole protein [3]. This pioneering
work initiated the whole field using peptides as efficient delivery
vectors for bioactive compounds, cell-penetrating peptides.
Since then, a myriad of peptides has been reported to have
cell-penetrating properties. The peptides originate from differ-
ent classes; either naturally occurring peptide sequences such as
virally derived (TAT, VP22), from transcription factors (pAntp),
chimeric peptides (transportan, MGP) or synthetic (poly-
arginines, Pep-1), cf. Table 1.0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.02.012However, due to difficulties in understanding the true
mechanisms of CPP cellular uptake, the classification of CPPs
still remains to be clarified.
Although great achievements in studies of CPP have been
attained, a clear description of their properties is still not defined.
The CPP field has been under constant change during the
years and the uptake mechanism still remains ambiguous.
Several attempts have been made in order to elucidate the true
mechanism of peptide mediated uptake, but the results are
divergent between different reports and experiments. Even
when using the same peptide, results vary between different
publications. Furthermore, it seems apparent that different
peptides utilize different uptake pathways [4].
Early studies on CPP translocation mechanisms suggested
that the internalization of these peptides was not inhibited by
depletion of the cellular adenosine triphosphate (ATP) pool, low
temperature (+4 °C), or by inhibitors of endocytosis [5]. Neither
did chemical modifications of the peptide sequences, such as the
synthesis of retro-, enantio- or retroenantio-analogs, appear to
affect the internalization properties [6]. Therefore, translocation
was thought to result from direct transfer through the lipid
bilayer of the cell membrane.
Formation of inverted micelles was a proposed mechanism
for these uptakes, where cationic residues interact with the
negatively charged plasma membrane followed by invagination
of tryptophans into the membrane, inducing inverted micelle
formation [6]. The postulated mechanism of inverted micelle
formation seems to explain some aspects of CPP translocation
and still appear to hold for some peptides used in cellular
delivery of bioactive molecules.
Later studies, on the other hand, show that the CPP
translocation mostly is an energy-dependent process [7].
Proposed mechanisms involve extracellular heparane sulfate
[8] and different types of endocytosis [9,10] such as macro-
pinocytosis, clathrin-dependent-, caveoale-dependent- or cla-
thrin- and caveoale-independent endocytosis. It seems to us that
these processes do not necessarily contradict each other rather
demonstrating that peptide mediated membrane translocation is
mediated by several different pathways simultaneously, or that
different peptides utilize diverse uptake mechanisms depending
on their cargo and biophysical properties [11].
Table 1
A selection of commonly used CPP
Name Sequence a Origin Ref.
Penetratin, pAntp RQIKIWFQNRRMKWKKa D. melanogaster transcription factor [3]
HIV TAT peptide (48–60) GRKKRRQRRRPPQb Viral transcriptional regulator [33]
HSV-1 VP22 peptide DAATATRGRSAASRPTERPRAPARSASRPRRVD Viral Capsid protein [34]
MAP (Model amphiphilic peptide) KLALKLALKALKAALKLA-amide Synthetic [35]
Transportan GWTLNSAGYLLGKINLKALAALAKKIL-amide Chimeric galanin-mastoparan [36]
R7 RRRRRRR Synthetic [37]
MPG GALFLGWLGAAGSTMGAPKKKRKVc Chimeric HIV-1 gp41-SV40 large T antigen [38]
Pep-1 KETWWETWWTEWSQPKKKRKVc Synthetic [26]
a All peptides are C-terminal free acids unless stated otherwise.
b One selected sequence, may vary from different studies.
c C-terminally modified with a cysteamide group.
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pathways contribute to the major route of uptake of CPPs,
although several reports show an uptake independent of
endocytosis [4,12,13]. The uptake mechanism could also be
altered by different cargoes, if the peptides form a stable
complex with its cargo, if the cargo is covalently bound to a
CPP or how the cargo is attach [14] (Fig. 1).
2. Targeted and enhanced delivery
Since CPPs penetrate virtually any all cell type both in vivo
and in vitro, the delivery seems to utilize a pathway(s) present in
all cells. This common feature makes CPP applicationsFig. 1. Suggested uptake mechanisms for CPPs and examples of delivered cargoes.
covalently linked. (C) Plasmid in complex by electrostatic interaction. (D) Protein eit
complex.complicated in pharmaceutical use. The peptides seem to
enter any and every cell they get in contact with, which restricts
CPP application as a pharmaceutical tool greatly. Recent results,
however, show promising results in targeted CPP delivery
[15,16], By exploiting explicit cell features such as extra-
cellular receptors and proteases or addition of cell specific
ligands such as small molecules, vitamins, carbohydrates, other
peptides or proteins (growth factors or antibodies) to known
CPPs may improve targeted delivery [17].
The stability ofpeptidevectors is anotherproblemregarding in
vivodelivery. If thevectordoesnot remain intactuntil it reaches its
target, it could domore harm than good. This ismost often solved
by using the D-form [18], instead of naturally occurring L-amino(A) CPP and peptide in single amino acid chain. (B) ON either in complex or
her as fusion protein or in complex with CPP. (E) siRNA, covalently linked or as
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and remains intact for a longer time when injected in vivo. Other
possibilities are to use peptide mimics such as beta-peptides [19]
or peptoids [20] to enhance vector stability.
To increase delivery yield, functional groups can be included
in the CPP sequence. For instance, addition of 20 amino acids
from the pH-sensitive fusogenic peptide HA2 derived from the
N-terminal part of influenza virus hemagglutinin protein, to a
TAT-peptide fusion protein enhanced protein uptake signifi-
cantly [21]. HA2 is a pH-sensitive fusogenic peptide that
destabilizes lipid membranes at low pH and thereby enhances
endosomal escape which leads to improved delivery [22].
3. Commercially available peptides
In recent years, biotech companies have shown interest in
CPP technologies, and some CPPs have become commercially
available. Most well known is probably the transport system
Chariot (Active Motif, France, http://www.activemotif.com),
formally known as Pep-1 (Table 1). Chariot is distributed as a
protein transfection agent that uses non-covalent interactions
with the macromolecule of interest to be delivered. The uptake is
fast (about 2 h) and it stabilizes proteins protecting it from
degradation during the transfection process. After delivery, the
peptide dissociates from the delivered molecule, leaving it
biologically active and free to proceed to its objective. Delivery
is proposed to be non-toxic and independent of the endosomal
pathways.
Other examples are the SynB vectors [23] from Synt:em
(www.syntem.com), France, and Express-si Delivery from
Genospectra (http://www.genospectra.com) U.S.A.
SynB vectors are a new family of vectors derived from the
antimicrobial peptide protegrin 1 (PG-1), an 18 amino acid
peptide originally isolated from porcine leucocytes. These
vectors were applied for delivery of e.g. doxorubicin and
camptothecin, both well-known anti-cancer drugs.
Express-si is based on the MPG peptide (Table 1) and is
distributed as a siRNA and oligonucleotide delivery vector. The
uptake mechanism is like Chariot proposed to be receptor-
independent and does not utilize endocytic pathways.
These examples, together with published reports from
pharma-industry on CPP applications, demonstrate clearly the
future perspective of CPPs in drug development.
4. Delivery of proteins
To use CPPs as vectors for protein delivery can have many
advantages over the more traditional approach to endogenously
express the desired protein from a plasmid such as difficulties
with transfection and varied protein expression in various cell
lines. Several proteins have been transported into cells by CPP
mediated translocation including proteins involved in apoptosis
[24], cell cycle regulation and DNA recombination [21].
By designing a plasmid coding for of a CPP in coding frame
with the desired protein, a cell permeable fusion protein is
produced. This method has successfully been applied both in
vivo and in vitro [25]. Addition of a highly cationic peptide inthe same amino acids chain as a protein may interfere with the
proteins tertiary structure and thereby cause loss of biological
function. This problem can be overcome by simply co-incubate
a CPP and the desired protein and thus facilitate cellular uptake
[26]. The protein thereby keeps its native structure and the
proteins biological properties are conserved.
5. Delivery of siRNA and other oligonucleotides
Many oligonucleotides and their modified analogues have
been reported to be delivered efficiently by CPPs into several
cell lines both in vivo [27] and in vitro [28]. Oligonucleotides
(ON) delivered by CPPs include antisense-ON [27], DNA
decoy-ON [29], siRNA [30] and plasmids [31].
RNA induced gene silencing through siRNA has emerged as
a powerful tool in recent years. As for many other biologically
active compounds, delivery over the plasma membrane remains
one of the major obstacles in siRNA applications. A few
peptides have been shown to improve siRNA uptake and down-
regulate the desired gene. The CPP and siRNA have either been
covalently linked via a disulfide bond [32], or the RNA and the
peptide form a complex through electrostatic interactions [30]
and are translocated across the plasma membrane.
6. Future of CPP mediated transport
Despite the ongoing research concerning the actual transport
pathway utilized by CPPs, they have been shown to efficiently
deliver a wide variety of bioactive compounds into a number of
cell lines in vitro. In vivo, CPPs can cross the blood–brain
barrier and mediate delivery to several organs. Targeted delivery
by CPP is a possible goal, and recent reports show great promise
in this field. There is an increasing need for an efficient, non-
toxic, non-hazardous transport vector. Cell-penetrating peptides
fulfill all of these criteria and may in the future be an important
tool in pharmaceutical research.
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